U.S. Markets open in 8 hrs 39 mins
  • S&P Futures

    4,261.75
    +7.00 (+0.16%)
     
  • Dow Futures

    34,420.00
    +39.00 (+0.11%)
     
  • Nasdaq Futures

    14,138.00
    +13.25 (+0.09%)
     
  • Russell 2000 Futures

    2,326.30
    +2.70 (+0.12%)
     
  • Crude Oil

    71.10
    +0.22 (+0.31%)
     
  • Gold

    1,866.60
    +0.70 (+0.04%)
     
  • Silver

    27.79
    -0.25 (-0.89%)
     
  • EUR/USD

    1.2129
    +0.0006 (+0.0485%)
     
  • 10-Yr Bond

    1.5010
    0.0000 (0.00%)
     
  • Vix

    16.39
    +0.74 (+4.73%)
     
  • GBP/USD

    1.4114
    +0.0006 (+0.0452%)
     
  • USD/JPY

    110.0640
    +0.0030 (+0.0027%)
     
  • BTC-USD

    40,532.88
    +1,283.99 (+3.27%)
     
  • CMC Crypto 200

    1,017.02
    +48.18 (+4.97%)
     
  • FTSE 100

    7,146.68
    +12.62 (+0.18%)
     
  • Nikkei 225

    29,440.66
    +278.86 (+0.96%)
     

Merck Teams Up With Five Indian Generic Players To Expand COVID-19 Drug Access, Production

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Merck & Co Inc (NYSE: MRK) has partnered with five Indian generic drugmakers to expand production and access to Molnupiravir, its experimental oral therapeutic for the treatment of COVID-19.

  • A part of these non-exclusive voluntary licensing agreements includes Cipla Ltd, Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd (NYSE: RDY), Emcure Pharmaceuticals Limited, and Hetero Labs Limited.

  • The partnership will give the companies license to supply Merck's molnupiravir to India and more than 100 low-and middle-income countries following approvals or emergency authorization by local regulatory agencies.

  • Gilead Sciences Inc (NASDAQ: GILD) also came forward to support India amid surging COVID-19 cases. It would give India at least 450,000 vials of its antiviral drug, remdesivir, and help boost production in India.

  • Molnupiravir is an antiviral therapy Merck is developing with Ridgeback Biotherapeutics to treat non-hospitalized COVID-19 patients.

  • Last month the companies announced interim Phase 2 data, demonstrating a significant reduction in the infectious virus in COVID-19 patients after five days of treatment.

  • Price Action: MRK shares are down 0.09% at $77.53 in premarket trading on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.